Pretax income is the income that a company earns before paying income taxes. EyePoint Pharmaceuticals's pretax income for the
three
months ended in Dec. 2023 was €-12.85 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €-65.59 Mil.
EyePoint Pharmaceuticals's pretax margin was -99.91%.
During the past 13 years, EyePoint Pharmaceuticals's highest Pretax Margin was 24.25%. The lowest was -1795.71%. And the median was -246.08%.
EyePoint Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of EyePoint Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, EyePoint Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EyePoint Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where EyePoint Pharmaceuticals's Pre-Tax Income falls into.
EyePoint Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
EyePoint Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-65.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint Pharmaceuticals (STU:PV3B) Pre-Tax Income Explanation
EyePoint Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, EyePoint Pharmaceuticals's highest Pretax Margin was 24.25%. The lowest was -1795.71%. And the median was -246.08%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
EyePoint Pharmaceuticals (STU:PV3B) Business Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:PV3B has been successfully added to your 